



## CASE REPORT

## D-Penicillamine induced elastosis perforans serpiginosa with involvement of glans penis

Yao-Nien Chuang<sup>1</sup>, Chun-An Yao<sup>1</sup>, Tsu-Man Chiu<sup>1</sup>, Kuo-Chia Yang<sup>1</sup>, Yueh-Min Lin<sup>2</sup>, Hsiu-Cheng Hsu<sup>1,\*</sup><sup>1</sup> Department of Dermatology, Changhua Christian Hospital, Changhua, Taiwan<sup>2</sup> Department of Pathology, Changhua Christian Hospital, Changhua, Taiwan

## ARTICLE INFO

## Article history:

Received: Mar 23, 2013

Revised: May 28, 2013

Accepted: Jun 4, 2013

## Keywords:

D-penicillamine

elastosis perforans serpiginosa

glans penis

Wilson disease

## ABSTRACT

Elastosis perforans serpiginosa (EPS) is an unusual perforating disorder characterized by extrusion of altered elastic fibers through the epidermis. Clinically, it presents as keratotic papules with a tendency for serpiginous or annular distribution that most commonly involves the sides of the neck and the back. However, involvement of the penis has rarely been reported. We present a case of EPS involving the neck, axilla, and glans penis in a 42-year-old man who had received long-term D-penicillamine treatment for Wilson disease. Skin biopsy revealed perforating channels containing numerous altered elastic fibers, with a characteristic “bramble brush” or “lumpy-bumpy” appearance as demonstrated by an elastin stain. The latter is thought to be pathognomonic for penicillamine-induced degenerative elastosis. These degenerative changes occurring in glans penis have rarely been described in the literature. Prompt recognition of the rare presentation could lead to early discontinuation of the offending drug, to prevent further sequelae.

Copyright © 2013, Taiwanese Dermatological Association.

Published by Elsevier Taiwan LLC. All rights reserved.

## Introduction

Elastosis perforans serpiginosa (EPS) is recognized as one of the four classical primary perforating disorders, along with reactive perforating collagenosis, perforating folliculitis, and Kyrle disease. It is known to occur in association with other systemic diseases, particularly inherited connective tissue disorders such as Ehlers-Danlos syndrome, osteogenesis imperfecta, pseudoxanthoma elasticum, or Marfan syndrome.<sup>1</sup> It is also a well-recognized potential complication of long-term D-penicillamine therapy. Here, we present a case illustrating the typical histological findings of D-penicillamine-induced EPS, including characteristic “bramble brush” or “lumpy-bumpy” alterations of elastic fibers, with an extremely rare clinical presentation involving the glans penis. The skin eruptions of our case developed on the glans penis initially without typical annular or serpiginous configuration, which could make it difficult to diagnosis accurately. Our case highlights that EPS should be considered as a differential diagnosis at this site.

Conflicts of interest: The authors declare that they have no financial or non-financial conflicts of interest related to the subject matter or materials discussed in this article.

\* Corresponding author. Department of Dermatology, Changhua Christian Hospital, No. 135, Nanhsiao Street, Changhua City, Changhua County 500, Taiwan. Tel.: +886 4 7238595; fax: +886 4 7232942.

E-mail address: [145900@cch.org.tw](mailto:145900@cch.org.tw) (H.-C. Hsu).

## Case report

A 42-year-old male patient presented to our dermatology department with a history of progressive, slightly itchy skin eruptions initially on the glans penis, then spreading to neck and axilla during the previous 2 months. He had been diagnosed with Wilson disease when he was 26 years old and had received long-term treatment with D-penicillamine (600 mg, three-times daily) for more than 16 years. Physical examination revealed erythematous to dusky red keratotic papules, that had a tendency to coalesce into annular and serpiginous plaques, with a central clearing on both sides of the neck and axillary areas (Figure 1A and B). There were also several discrete erythematous papules with central keratotic plugs on the glans penis (Figure 1C and D). Skin biopsy from the axilla and glans penis revealed a localized area of irregular acanthosis with broadened rete ridges and epidermal invagination surrounding basophilic inflammatory debris and eosinophilic material that formed configuring perforating channels (Figure 2A and B). At a higher magnification, degenerated cells, mixed inflammatory cells, and inflammatory debris with an accumulation of eosinophilic fragmented fibers at the base of channels, could be seen in the perforating channels (Figure 2C and D). An elastin stain showed numerous irregular, coarse, and fragmented elastic fibers within the channels (Figure 2E). At a higher magnification, multiple



**Figure 1** (A) Erythematous to dusky red keratotic papules coalescing to form annular or serpiginous plaques with a central clearing on both sides of the neck occurred in this 42-year-old man. The patient had been on long-term treatment with D-penicillamine for Wilson disease; (B) serpiginous plaques with a central clearing and atrophy near the axilla were observed in the same patient; and (C, D) several erythematous papules with central keratotic plugs were seen on the glans penis of the same patient (arrow).

serrations and buds arising perpendicularly from the surface of the irregular elastic fibers, producing a characteristic “bramble brush” or “lumpy-bumpy” appearance, were observed (Figure 2F).

According to the clinical observations and histological findings, a diagnosis of D-penicillamine-induced EPS was made. We initially administered topical tazarotene gel, but the patient could not tolerate the side effects that included peeling and irritation. He was further treated with cryotherapy. Although some of the previous lesions showed partial regression after treatment, some continued to progress. After consulting with the patient’s neurologist, we substituted trientine dihydrochloride for D-penicillamine to control the symptoms of Wilson disease. The skin lesions stopped progressing, leaving central atrophic scars during a 1-year follow-up (Figure 3A and B).

## Discussion


EPS is a rare perforating dermatosis characterized by transepidermal elimination of altered elastic fibers. These conditions are characterized by the clinical presentation of hyperkeratotic papules that occur in a serpiginous arrangement, with the microscopic characteristic of transepidermal elimination of abnormal elastic fibers. It is a rare disorder that mainly affects adolescents or young adults, with a 4:1 male predominance.<sup>2</sup> It has traditionally been classified into the following three subtypes: idiopathic; secondary to treatment with D-penicillamine; or associated with other systemic, inherited, fibrous tissue abnormalities such as Down syndrome, Marfan syndrome, acrogeria, pseudoxanthoma elasticum, osteogenesis imperfecta, Rothmund-Thomson syndrome, Ehlers-Danlos syndrome, or scleroderma. Once the diagnosis of EPS is made, the clinician should investigate the possibility of comorbid states or penicillamine therapy. Some experts recommend ophthalmologic examination and cardiac echocardiography,

whereas others defer such investigations beyond a thorough patient history and physical examination.<sup>1</sup>

The exact cause of EPS is unknown, but it has been suggested that the primary abnormality is possibly in the dermal elastin, which provokes a cellular response leading to the extrusion of abnormal elastic tissue.<sup>3</sup> Fujimoto et al demonstrated that elastin could be a potent inducer of migration and terminal differentiation of cultured keratinocytes, mediated by the 67 kDa elastin receptor.<sup>4</sup> The receptor is abundantly expressed in the active peripheral keratotic area of EPS and appears to be related to the elastic fiber content in the dermal material.<sup>5</sup> It has been postulated that the elastin-keratinocyte interaction, mediated by the elastin receptors, plays an important role in the transepidermal elimination of elastin, inducing EPS.

D-Penicillamine has been used as one of chelating agents and disease modifying antirheumatic drugs in the treatment of Wilson disease, cystinuria, rheumatoid arthritis, and scleroderma.<sup>6</sup> The most common adverse effects of D-penicillamine are cutaneous, occurring in approximately 25–50% of patients. These adverse effects can be classified into four groups based on the induction mechanism, including: (1) interference with collagen and elastin such as pseudoxanthoma elasticum, cutis laxa, and mucosal elastosis; (2) acute sensitivity reactions such as urticaria and exanthematous drug-induced eruption; (3) autoimmune mechanisms such as bullous and lupus-like reactions; and (4) miscellaneous dermatoses that result from undefined mechanisms.<sup>7,8</sup> The postulated mechanisms relevant to collagen and elastic fibers include: (1) direct inhibition of collagen synthesis, a well-known effect of D-penicillamine for the treatment of scleroderma that further interferes with elastic fiber cross-linking; and (2) copper deficiency secondary to D-penicillamine treatment at higher doses, that impairs the lysyl oxidase activity on elastic fiber desmosine cross-linking, a crucial process in fiber stabilization.<sup>7,9</sup> Accordingly, the





**Figure 2** (A) A skin biopsy from the axilla showed irregular acanthosis with broadened rete ridges, epidermal invagination surrounding basophilic inflammatory debris and eosinophilic fragmented fibers that formed perforating channels [hematoxylin and eosin (H and E, 40 $\times$ )]; (B) another skin biopsy taken from the glans penis indicated a localized area of acanthosis surrounding the perforating channels, through which inflammatory debris and eosinophilic fragmented fibers were being eliminated [hematoxylin and eosin (H and E, 40 $\times$ )]; (C) the perforating channels of an axillary skin biopsy containing degenerated cell debris, mixed inflammatory cells, and inflammatory debris, with an accumulation of eosinophilic fragmented fibers at the base of channels [hematoxylin and eosin (H and E, 40 $\times$ )]; (D) the perforating channels of a penile biopsy containing a mixed inflammatory infiltrate of predominantly neutrophils, cell debris, and fragmented fibers at the base of the channels [hematoxylin and eosin (H and E, 40 $\times$ )]; (E) numerous irregular thickened and fragmented elastic fibers within the channels were revealed by an elastin stain (orcein stain, 100 $\times$ ); and (F) perpendicular budding from the surface of the irregular elastic fibers formed a serrated border (arrow) giving a characteristic “bramble brush” or “lumpy-bumpy” appearance at a higher magnification (orcein stain, 400 $\times$ ).


accumulation of abnormal elastic fibers could provoke a foreign body reaction, by inducing elastin-keratinocyte interactions, and subsequently transepidermal extrusion of abnormal elastic fibers developed, which caused the hallmark indication of EPS. D-Penicillamine-induced EPS is almost exclusively associated with long-term therapy for Wilson disease and cystinuria, probably because these drug effects require prolonged administration of D-penicillamine at high dose (1 g daily for more than 5 years).<sup>10</sup> The cumulative dosage and duration of D-penicillamine in our patient is 1800 mg daily for about 16 years.

Previous reports of D-penicillamine-induced EPS showed that it could coexist with other cutaneous adverse effects related to elastic fiber alteration, such as pseudoxanthoma elasticum,<sup>11,12</sup> cutis laxa,<sup>7,13,14</sup> and mucosal elastosis.<sup>15,16</sup> Some authors have suggested that dermatoses should be considered as different expressions of the same degenerative process and reclassified as one entity, “penicillamine-induced degenerative dermatosis”.<sup>17</sup> Moreover, the D-penicillamine-induced elastic fiber alteration yields a peculiar histopathologic feature – serrated appearance of elastic fibers due

to perpendicular budding from their surface, giving a “bramble brush” or “lumpy-bumpy” appearance<sup>3,18</sup> – as demonstrated in our case. This distinct degenerative elastolytic change could be seen in patients with D-penicillamine-induced degenerative dermatosis. Similar elastic fiber changes have also been reported to occur in nonlesional skin,<sup>3</sup> artery,<sup>19</sup> upper respiratory tract,<sup>20</sup> and lung.<sup>21</sup> Such widespread changes may suggest ongoing, potentially serious systemic effects caused by elastic fiber damage.

Numerous treatment methods for EPS have been described, although there is no “gold standard” therapy. Anecdotally reported effective therapies include oral isotretinoin,<sup>22</sup> topical tazarotene,<sup>23</sup> imiquimod,<sup>24</sup> narrow-band ultraviolet B, calcipotriene,<sup>25</sup> cryotherapy,<sup>26</sup> and laser ablation.<sup>27</sup> D-Penicillamine therapy to treat Wilson disease can be substituted by the administration of alternative medications such as zinc salts, which block the intestinal absorption of copper, and trientine dihydrochloride, another copper chelator with less toxicity.<sup>16,28</sup> In the patient of the present case, discontinuation of penicillamine therapy stopped the progression of EPS. However, multiple case reports have described the abrupt





**Figure 3** (A) Previous skin lesions on side of the neck stopped progressing, leaving central atrophic scars 1-year after discontinuation of D-penicillamine use; and (B) the skin lesions on the glans penis left several depressed scars with slightly elevated erythematous borders.

onset or EPS recurrence months to years after terminating penicillamine therapy.<sup>11,13,15</sup> These events are probably related to the cumulative dose and slow clearance of the drug, with the remaining effects observed on the elastic tissue.<sup>13</sup>

To the best of our knowledge, glans penis is an extremely rare site that develops EPS. Roest and Ratnavel reported the case of a 44-year-old man with D-penicillamine-induced EPS on the glans penis with cystinuria.<sup>29</sup> It presented as a single, isolated erythematous scarring plaque with a pale depressed center on the glans penis that developed after recurrent episodes of asymptomatic ulceration, without coexistent EPS at other sites. This finding was different from that in our patient. As mentioned above, D-penicillamine-induced degenerative changes of elastic fibers could be found in the skin, mucosa, and other visceral organs; therefore, it is reasonable that similar changes can occur in the glans penis to cause penile EPS.

In conclusion, we present a case of EPS caused by long-term administration of D-penicillamine with the involvement of glans penis. The atypical presentation and rarity of the disease could cause delayed diagnoses or misdiagnoses. This disease is important, as it represents a degenerative process induced by D-penicillamine and probably represents only the tip of the iceberg because of the potential involvement of other nonlesional skin and visceral organs. Prompt recognition of these adverse cutaneous effects and discontinuation of the drug may be necessary to prevent the possible occurrence of systemic sequelae.

## References

- Vearrier D, Buka RL, Roberts B, Cunningham BB, Eichenfield LF, Friedlander SF. What is standard of care in the evaluation of elastosis perforans serpiginosa? A survey of pediatric dermatologists. *Pediatr Dermatol* 2006;**23**:219–24.
- Diaz GJ, Berk D, Bruckner AL, Kim J. Annular and keratotic papules and plaques in a teenager. Elastosis perforans serpiginosa (EPS). *Arch Dermatol* 2009;**145**:931–6.
- Khatu SS, Dhurat RS, Nayak CS, Pereira RR, Kagne RB. Penicillamine-induced elastosis perforans serpiginosa with abnormal "lumpy-bumpy" elastic fibers in lesional and non-lesional skin. *Indian J Dermatol Venereol Leprol* 2011;**77**:55–8.
- Fujimoto N, Tajima S, Ishibashi A. Elastin peptides induce migration and terminal differentiation of cultured keratinocytes via 67 kDa elastin receptor *in vitro*: 67 kDa elastin receptor is expressed in the keratinocytes eliminating elastic materials in elastosis perforans serpiginosa. *J Invest Dermatol* 2000;**115**: 633–9.
- Fujimoto N, Akagi A, Tajima S, et al. Expression of the 67-kDa elastin receptor in perforating skin disorders. *Br J Dermatol* 2002;**146**:74–9.
- Poon E, Mason GH, Oh C. Clinical and histological spectrum of elastotic changes induced by penicillamine. *Australas J Dermatol* 2002;**43**:147–50.
- Rosen LB, Muellenhoff M, Tran TT, Muhart M. Elastosis perforans serpiginosa secondary to D-penicillamine therapy with coexisting cutis laxa. *Cutis* 2005;**76**: 49–53.
- Popadic S, Skiljevic D, Medenica L. Bullous pemphigoid induced by penicillamine in a patient with Wilson disease. *Am J Clin Dermatol* 2009;**10**:36–8.
- Atzori L, Pinna AL, Pau M, Aste N. D-Penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. *Dermatol Online J* 2011;**17**:3.
- Carlesimo M, Narcisi A, Cortesi G, et al. An 18-year follow-up of a case of D-penicillamine-induced elastosis perforans serpiginosa. *Int J Immunopathol Pharmacol* 2011;**24**:257–9.
- Becuwe C, Dalle S, Ronger-Savle S, et al. Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine. *Dermatology* 2005;**210**:60–3.
- Meyer S, Zanardo L, Kaminski WE, et al. Elastosis perforans serpiginosa-like pseudoxanthoma elasticum in a child with severe Moya Moya disease. *Br J Dermatol* 2005;**153**:431–4.
- Na SY, Choi M, Kim MJ, Lee JH, Cho S. Penicillamine-induced elastosis perforans serpiginosa and cutis laxa in a patient with Wilson's Disease. *Ann Dermatol* 2010;**22**:468–71.
- Hill VA, Seymour CA, Mortimer PS. Penicillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson's disease. *Br J Dermatol* 2000;**142**:560–1.
- Lewis BK, Chern PL, Stone MS. Penicillamine-induced elastosis of the mucosal lip. *J Am Acad Dermatol* 2009;**60**:700–3.
- Tovaru S, Parlatescu I, Dumitriu AS, Bucur A, Kaplan I. Oral complications associated with D-penicillamine treatment for Wilson disease: a clinicopathologic report. *J Periodontol* 2010;**81**:1231–6.
- Iozumi K, Nakagawa H, Tamaki K. Penicillamine-induced degenerative dermatoses: report of a case and brief review of such dermatoses. *J Dermatol* 1997;**24**:458–65.
- Gebhart W, Bardach H. The "lumpy-bumpy" elastic fiber. A marker for long-term administration of penicillamine. *Am J Dermatopathol* 1981;**3**:339.
- Price RG, Prentice RS. Penicillamine-induced elastosis perforans serpiginosa. Tip of the iceberg? *Am J Dermatopathol* 1986;**8**:314–20.
- Manohar MB, Boldy DA, Bryan RL, Pearman K. Penicillamine-induced changes in elastic tissue of the upper respiratory tract. *J Laryngol Otol* 1993;**107**:62–4.
- Bardach H, Gebhart W, Niebauer G. "Lumpy-bumpy" elastic fibers in the skin and lungs of a patient with a penicillamine-induced elastosis perforans serpiginosa. *J Cutan Pathol* 1979;**6**:243–52.
- Ratnavel RC, Norris PG. Penicillamine-induced elastosis perforans serpiginosa treated successfully with isotretinoin. *Dermatology* 1994;**189**:81–3.
- Outland JD, Brown TS, Callen JP. Tazarotene is an effective therapy for elastosis perforans serpiginosa. *Arch Dermatol* 2002;**138**:169–71.
- Kelly SC, Purcell SM. Imiquimod therapy for elastosis perforans serpiginosa. *Arch Dermatol* 2006;**142**:829–30.
- Mehta RK, Burrows NP, Payne CM, Mendelsohn SS, Pope FM, Rytina E. Elastosis perforans serpiginosa and associated disorders. *Clin Exp Dermatol* 2001;**26**: 521–4.
- Humphrey S, Hemmati I, Randhawa R, Crawford RI, Hong CH. Elastosis perforans serpiginosa: treatment with liquid nitrogen cryotherapy and review of the literature. *J Cutan Med Surg* 2010;**14**:38–42.
- Yang JH, Han SS, Won CH, et al. Treatment of elastosis perforans serpiginosa with the pinhole method using a carbon dioxide laser. *Dermatol Surg* 2011;**37**: 524–6.
- Wiggelinkhuizen M, Tilanus ME, Bollen CW, Houwen RH. Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. *Aliment Pharmacol Ther* 2009;**29**:947–58.
- Roest MA, Ratnavel R. Elastosis perforans serpiginosa of the penis. *BJU Int* 2003;**91**:427.